Effectiveness of Aligners Versus Rapid Maxillary Expansion

Maxillary Transverse Deficiency (MTD) Clinical Trial

Official title:

Effectiveness of Aligners Versus Rapid Maxillary Expansion on 3D Palatal Volume in Mixed Dentition Patients: a Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04760535
• Other study ID #: Maxillary Expansion
• Status: Completed
• Phase: N/A
• Start date: January 15, 2019
• Est. completion date: May 3, 2021

Study information

• Verified date: May 2022
• Source: University of Turin, Italy
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aim of the study is to assess the effectiveness of Invisalign® First clear aligners compared to tooth-borne Hyrax-type maxillary expander on palatal morphology in growing subjects using 3D technology.

Description:

Aim of the study is to assess the effectiveness of Invisalign® First clear aligners compared to tooth-borne Hyrax-type maxillary expander on palatal morphology in growing subjects using 3D technology. This two-arm parallel-group randomized prospective clinical trial will include patients with: indications for maxillary expansion treatment, age between 6 and 10 years old, mixed dentition, good standard of oral hygiene, good compliance during treatment as assessed by the practitioner. Patients will be assigned to one of two expansion methods (arm A: Invisalign® First clear aligners, arm B: tooth-borne Hyrax-type maxillary expander) according to a computer-generated randomization list shortly before the start of expansion Primary outcome measure will be the change in palatal morphology (palatal volume and surface area variations). Secondary outcomes will be: arch dimensions (upper inter-canine width, upper inter-molar width, anterior segment length, posterior segment length), complications, patients' satisfaction and periodontal health. Due to the nature of the intervention blinding will not be possible. Potential statistical differences between the two intervention groups will be evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: May 3, 2021
• Est. primary completion date: October 15, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 10 Years

Eligibility

Inclusion Criteria:

• patients who have been diagnosed with transverse maxillary deficiency;

• mixed dentition phase with cervical vertebral maturation stage (CVMS) less than 4;

• fully erupted upper and lower first molars;

• transversal discrepancy =5mm

• demonstration of a good standard of oral hygiene (determined through questioning and clinical examination);

• subjects willing to consent to the trial and comply with the trial regime.

Exclusion Criteria:

• any general medical health problems which may influence gingival health, such as those necessitating antibiotic cover as bacteremia prophylaxis, diabetes mellitus, epilepsy, or physical or mental disability;

• permanent teeth extraction-based treatment (third molars excluded);

• morphologic crown anomalies;

• auxiliary treatment during arch expansion stage (such as crossbite elastics);

• posterior interproximal reduction;

• orthognathic surgery treatment planned;

• cleft palate or severe facial deformities.

Related Conditions & MeSH terms

• Maxillary Transverse Deficiency (MTD)

Intervention

Device:
• Invisalign® First Phase I treatment (Align Technology, Inc., Santa Clara, CA, USA)
Subjects in this arm will be instructed to wear aligners 24h/day for entire duration of the therapy. They will be asked to remove their retainers only while eating, drinking (except water), or cleaning. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
• Tooth-borne Hyrax-type maxillary expander
The expansion protocol was one quarter-turn twice a day (0.45 mm activation per day) until overcorrection with the maxillary lingual cusps contacting the mandibular buccal cusps. The expander was left passively for retention for a minimum of 6 months. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.

Locations

Country	Name	City	State
Italy	University of Turin	Turin

Sponsors (1)

Lead Sponsor	Collaborator
University of Turin, Italy

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Palate morphology	The primary outcome will be to evaluate the changes in palatal morphology after the treatment of maxillary deficiencies using two different therapies and to re-evaluate changes over the initial 12-months after the end of the treatment. The changes in palatal morphology are defined as the variation in palatal volume and surface. These will be measured from digitized study models within the boundaries of the palate, the gingival and distal planes, defined as follow. The gingival plane will be created by connecting the midpoints of the dentogingival junction of all upper erupted deciduous and permanent teeth. The distal plane will be created through two points at the distal of the first upper permanent molars perpendicular to the gingival plane.	12 months
Secondary	Upper inter-canine width (ICW)	Upper inter-canine width (ICW) (secondary outcome measure) is the transverse distance between upper canines in millimeters.	12 months
Secondary	Upper inter-molar width (IMW)	Upper inter-molar width (IMW) (secondary outcome measure) is the transverse distance between upper first molars in millimeters.	12 months